A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

Autor: Mark J. Levis, Alexander E. Perl, Jessica K. Altman, Christopher D. Gocke, Erkut Bahceci, Jason Hill, Chaofeng Liu, Zhiyi Xie, Andrew R. Carson, Valerie McClain, Timothy T. Stenzel, Jeffrey E. Miller

Publikováno v: Blood Advances, Vol 2, Iss 8, Pp 825-831 (2018)

Abstract: Internal tandem duplications in fms-like tyrosine kinase 3 (FLT3-ITDs) are common in acute myeloid leukemia (AML) and confer a poor prognosis. A sensitive and specific assay for the detection of minimal residual disease (MRD) in FLT3-ITD mu

Externí odkaz: https://doaj.org/article/634a162263cd4003a1da4900188a1d86

First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors

Autor: Tianhong Li, Patricia LoRusso, Michael L. Maitland, Sai-Hong Ignatius Ou, Erkut Bahceci, Howard A. Ball, Jung Wook Park, Geoffrey Yuen, Anthony Tolcher

Publikováno v: Journal of Hematology & Oncology, Vol 9, Iss 1, Pp 1-9 (2016)

Abstract Background ASP3026 is a second-generation anaplastic lymphoma kinase (ALK) inhibitor that has potent in vitro activity against crizotinib-resistant ALK-positive tumors. This open-label, multicenter, first-in-human phase I study ( NCT01284192

Externí odkaz: https://doaj.org/article/6df78f3e3340454c8deb3c23b520004a

The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation–positive relapsed/refractory acute myeloid leukemia

Autor: Jason E. Hill, Jessica K. Altman, Mark J. Levis, Erkut Bahceci, Alexander E. Perl, Matt Rosales

Publikováno v: Cancer Medicine
Cancer Medicine, Vol 10, Iss 3, Pp 797-805 (2021)

The FLT3 inhibitor gilteritinib has clinical activity in patients with FLT3‐mutated (FLT3 mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML). The impact of FLT3 mutation clearance and the achievement of composite complete remission (CRc)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c6535ac028d54fe99ce69277c038b3f
http://europepmc.org/articles/PMC7897940

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML

Autor: Robert K. Stuart, Je-Hwan Lee, Andreas Neubauer, Jorge E. Cortes, Richard A. Larson, Timothy S. Pardee, Mark J. Levis, Chaofeng Liu, Harry P. Erba, Sung Soo Yoon, Celalettin Ustun, Ellin Berman, Maria R. Baer, Nikolai A. Podoltsev, Wen-Chien Chou, Giovanni Martinelli, Nahla Hasabou, Pau Montesinos, Antonio Di Stasi, Stefania Paolini, Alexander E. Perl, Francesco Fabbiano, Hisayuki Yokoyama, Xuan Liu, Margaret Kasner, Rebecca L. Olin, Naoko Hosono, Erkut Bahceci, Amir T. Fathi, Fabio Ciceri, Christian Recher

Publikováno v: NEW ENGLAND JOURNAL OF MEDICINE
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

BACKGROUND Patients with relapsed or refractory acute myeloid leukemia (AML) with mutations in the FMS-like tyrosine kinase 3 gene (FLT3) infrequently have a response to salvage chemotherapy. Gilteritinib is an oral, potent, selective FLT3 inhibitor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccfc356647d2ab631545ce73456807d5
https://doi.org/10.1056/nejmoa1902688

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

Autor: Andrew R. Carson, Alexander E. Perl, Valerie McClain, Timothy T. Stenzel, Mark J. Levis, Jessica K. Altman, Jason Hill, Zhiyi Xie, Erkut Bahceci, Christopher D. Gocke, Chaofeng Liu, Jeffrey E. Miller

Publikováno v: Blood Advances. 2:825-831

Internal tandem duplications in fms-like tyrosine kinase 3 (FLT3-ITDs) are common in acute myeloid leukemia (AML) and confer a poor prognosis. A sensitive and specific assay for the detection of minimal residual disease (MRD) in FLT3-ITD mutated AML

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c65ce3f4d7493b96a502c262b720b947
https://doi.org/10.1182/bloodadvances.2018015925